Team:Westminster/Project

From 2012.igem.org

(Difference between revisions)
(→Project Details)
 
(13 intermediate revisions not shown)
Line 1: Line 1:
-
<!--- The Mission, Experiments --->
 
-
 
<html>
<html>
 +
<head>
<head>
-
<style type="text/css">
 
-
{
 
-
list-style-type:none;
 
-
margin:10;
 
-
padding:0;
 
-
}
 
-
a.navlink
 
-
{
 
-
display:block;
 
-
background-color:black;
 
-
width:102px;
 
-
height:30px;
 
-
font-family:verdana;
 
-
font-size:10pt;
 
-
color:white;
 
-
text-decoration: none;
 
-
text-align:center;
 
-
line-height: 30px;
 
-
position:relative;
 
-
float: left;
 
-
border-radius: 3px;
 
-
margin-right: 5px;
 
-
}
 
-
a.navlink:hover{
 
-
background-color:#459182;
 
-
}
 
-
</style>
 
-
</head>
 
-
<body>
+
<meta http-equiv="content-type" content="text/php; charset=utf-8" />
-
<a href="https://2012.igem.org/Team:Westminster" class="navlink">Home</a>
+
-
<a href="https://2012.igem.org/Team:Westminster/Team" class="navlink">Team</a>
+
-
<a href="https://igem.org/Team.cgi?year=2012&team_name=Westminster"class="navlink">Team Profile</a>
+
-
<a href="https://2012.igem.org/Team:Westminster/Project"class="navlink">Project</a>
+
-
<a href="https://2012.igem.org/Team:Westminster/Parts"class="navlink">Parts</a>
+
-
<a href="https://2012.igem.org/Team:Westminster/Modeling"class="navlink">Modeling</a>
+
-
<a href="https://2012.igem.org/Team:Westminster/Notebook"class="navlink">Notebook</a>
+
-
<a href="https://2012.igem.org/Team:Westminster/Safety"class="navlink">Safety</a>
+
-
<a href="https://2012.igem.org/Team:Westminster/Attributions"class="navlink">Attributions</a>
+
-
</body>
+
-
</html>
+
 +
<style type="text/css">
 +
@import url 'http://yui.yahooapis.com/2.9.0/build/reset/reset-min.css';
 +
ul {
 +
list-style: none;
 +
}
 +
body {
 +
font-family: "HelveticaNeue-Light", "Helvetica Neue Light", "Helvetica Neue", Helvetica, Arial, "Lucida Grande", sans-serif;
 +
font-weight: 300;
 +
background: url("http://www.westminsterigem.com/files/theme/body-bg.png") repeat #ffffff;
 +
color: #666666;
 +
}
 +
h1, h2 {
 +
color: #ff0000;
 +
font-size: 18pt;
 +
margin-bottom: 0.5em;
 +
}
 +
h2 {
 +
font-size: 16pt;
 +
}
 +
h3 {
 +
color: #ff0000;
 +
}
 +
p {
 +
 
 +
}
 +
a {
 +
 +
}
 +
#p-logo {
 +
background: #444444;
 +
}
 +
div#top-section,
 +
div#content {
 +
box-shadow: 0px 0px 17px -4px #666666;
 +
}
 +
div#wrapper {
 +
position: relative;
 +
width: 885px;
 +
font-size: 12pt;
 +
padding: 50px 40px;
 +
margin: 0 auto;
 +
background: #ffffff;
 +
}
 +
div#header {
 +
height: 185px;
 +
}
 +
div#header div#logo {
 +
position: relative;
 +
width: 400px;
 +
height: 125px;
 +
margin: 0 auto;
 +
}
 +
div#header div#logo {
 +
margin-bottom: 20px;
 +
}
 +
div#navigation {
 +
width: 100%;
 +
height: 40px;
 +
background: #000000;
 +
}
 +
ul#navigation-list {
 +
height: 40px;
 +
line-height: 40px;
 +
overflow: hidden;
 +
}
 +
ul#navigation-list > li {
 +
float: left;
 +
}
 +
ul#navigation-list > li > ul {
 +
position: absolute;
 +
display: none;
 +
background: #000000;
 +
z-index: 100000;
 +
}
 +
ul#navigation-list > li > ul.submenu {
 +
margin: 0;
 +
}
 +
ul#navigation-list > li > ul.submenu li {
 +
padding: 5px 0px;
 +
}
 +
ul#navigation-list a.navlink {
 +
color: #ffffff;
 +
font-weight: bold;
 +
display: block;
 +
padding: 0px 14px;
 +
text-decoration: none;
 +
}
 +
ul#navigation-list a.navlink.active,
 +
ul#navigation-list a.navlink:hover {
 +
color: #ff0000;
 +
}
 +
div#home-main-image {
 +
text-align: center;
 +
}
 +
div#home-main-image img {
 +
width: 885px;
 +
height: 300px;
 +
margin-bottom: 20px;
 +
border-radius: 20px;
 +
}
 +
div.text-box {
 +
background: #444444;
 +
color: #ffffff;
 +
padding: 15px 20px;
 +
border-radius: 10px;
 +
}
 +
div.three-columns {
 +
padding-left: 20px;
 +
overflow: auto;
 +
}
 +
div.column, img.column {
 +
float: left;
 +
width: 235px;
 +
margin: 10px 0px 50px 20px;
 +
border-radius: 10px;
 +
}
 +
div#footer-box {
 +
border-radius: 0 0 5px 5px;
 +
}
 +
</style>
 +
<script type="text/javascript" src="http://code.jquery.com/jquery-1.8.2.min.js"></script>
 +
<script type="text/javascript">
 +
$('document').ready(function() {
 +
$('li.submenu-holder').hover(function() {
 +
$(this).children('ul.submenu').stop(true).fadeIn('slow');
 +
}, function() {
 +
$(this).children('ul.submenu').stop(true).fadeOut('slow');
 +
});
 +
});
 +
</script>
-
== '''Overall project''' ==
+
</head>
-
Cancer recurrence is one of the fears that almost every patient undergoing chemotherapy develops. Recent findings suggest that only a small fraction of the tumor cells, called Cancer Stem Cells (CSCs) are able to drive the growth of the tumor. CSCs also show an increased drug resistance, and could remain unaffected after chemotherapy, eventually resulting in the formation of a new tumor.
+
<body>
-
The Westminster iGEM 2012 team aims to combat cancer recurrence by using one key feature of CSCs – increased Aldehyde Dehydrogenase (ALDH) activity. We aim to characterise the promoters for a range of ALDH isoforms and combine synthetic biology and fluorescence techniques to identify and eliminate these cells, offering a novel tool for cancer diagnosis and treatment.
+
<div id="wrapper">
-
== Project Details==
+
<div id="header">
 +
<div id="logo">
 +
<a href="https://2012.igem.org/Team:Westminster">
 +
<img src="https://static.igem.org/mediawiki/2012/1/1e/Westminster-logo.png" alt="iSTEM" title="Back to home!" />
 +
</a>
 +
</div><!-- #logo -->
 +
<div id="navigation">
 +
<ul id="navigation-list">
 +
<li><a href="https://2012.igem.org/Team:Westminster" class="navlink">Home</a></li>
 +
<li><a href="https://2012.igem.org/Team:Westminster/Team" class="navlink">Team</a></li>
 +
<li><a href="https://igem.org/Team.cgi?year=2012&team_name=Westminster"class="navlink">Team Profile</a></li>
 +
<li class="submenu-holder">
 +
<a href="https://2012.igem.org/Team:Westminster/Project/Overview"class="navlink active">Project</a>
 +
<ul class="submenu">
 +
<li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Overview"class="navlink active">Overview</a></li>
 +
<li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Problem"class="navlink">The Problem</a></li>
 +
<li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Experiments"class="navlink">Experiments</a></li>
 +
<li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Protocols"class="navlink">Protocols</a></li>
 +
<li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Results"class="navlink">Results</a></li>
 +
<li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Safety"class="navlink">Safety</a></li>
 +
<li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Journal"class="navlink">Journal</a></li>
 +
</ul>
 +
</li>
 +
<li><a href="https://2012.igem.org/Team:Westminster/Parts"class="navlink">Parts</a></li>
 +
<li><a href="https://2012.igem.org/Team:Westminster/Modeling"class="navlink">Modeling</a></li>
 +
<li><a href="https://2012.igem.org/Team:Westminster/Notebook"class="navlink">Notebook</a></li>
 +
<li><a href="https://2012.igem.org/Team:Westminster/Safety"class="navlink">Safety</a></li>
 +
<li><a href="https://2012.igem.org/Team:Westminster/Attributions"class="navlink">Attributions</a></li>
 +
</ul><!-- #navigation-list -->
 +
</div><!-- #navigation -->
 +
</div><!-- #header -->
 +
<div id="the-content">
 +
<div id="home-main-image">
 +
<img src="https://static.igem.org/mediawiki/2012/4/4d/Westminster_team.png" alt="Welcome" title="Welcome to our home!" />
 +
</div><!-- #home-main-image -->
 +
<div id="home-main-text">
 +
<h2>Lorem Ipsum</h2>
 +
<div class="three-columns">
 +
<img class="column" src="https://static.igem.org/mediawiki/2012/4/4d/Westminster_team.png" width="255" height="220" />
 +
<img class="column" src="https://static.igem.org/mediawiki/2012/4/4d/Westminster_team.png" width="255" height="220" />
 +
<img class="column" src="https://static.igem.org/mediawiki/2012/4/4d/Westminster_team.png" width="255" height="220" />
 +
</div><!-- #three-columns -->
 +
<h2>Lorem Ipsum</h2>
 +
<p>Cancer recurrence is one of the fears that almost every patient undergoing chemotherapy develops. Recent findings suggest that only a small fraction of the tumor cells, called Cancer Stem Cells (CSC) are able to drive the growth of the tumor. CSC also show an increased drug resistance, and could remain unaffected after chemotherapy, eventually resulting in the formation of a new tumor.</p>
 +
<h2>Lorem Ipsum</h2>
 +
<p>Cancer recurrence is one of the fears that almost every patient undergoing chemotherapy develops. Recent findings suggest that only a small fraction of the tumor cells, called Cancer Stem Cells (CSC) are able to drive the growth of the tumor. CSC also show an increased drug resistance, and could remain unaffected after chemotherapy, eventually resulting in the formation of a new tumor.</p>
 +
</div><!-- #home-main-text -->
 +
</div><!-- #the-content -->
 +
</div><!-- #wrapper -->
-
=== Part 2 ===
 
 +
</body>
-
 
+
</html>
-
 
+
-
 
+
-
=== The Experiments ===
+
-
 
+
-
 
+
-
 
+
-
 
+
-
=== Part 3 ===
+
-
 
+
-
== Results ==
+

Latest revision as of 19:53, 25 September 2012

Welcome

Lorem Ipsum

Lorem Ipsum

Cancer recurrence is one of the fears that almost every patient undergoing chemotherapy develops. Recent findings suggest that only a small fraction of the tumor cells, called Cancer Stem Cells (CSC) are able to drive the growth of the tumor. CSC also show an increased drug resistance, and could remain unaffected after chemotherapy, eventually resulting in the formation of a new tumor.

Lorem Ipsum

Cancer recurrence is one of the fears that almost every patient undergoing chemotherapy develops. Recent findings suggest that only a small fraction of the tumor cells, called Cancer Stem Cells (CSC) are able to drive the growth of the tumor. CSC also show an increased drug resistance, and could remain unaffected after chemotherapy, eventually resulting in the formation of a new tumor.

Retrieved from "http://2012.igem.org/Team:Westminster/Project"